Molecular markers additional to cytogenetics with independent prognostic significance for remission duration or survival in acute myeloid leukemia (AML) of adults.
| Marker . | Frequency . | (%) . | Predictive for Relapse . | Survival . | Reference . |
|---|---|---|---|---|---|
| *normal cytogenetics only. †AML with t(8;21) and inv(16) only. | |||||
| P53 mutation | 9/200 | 4.5 | -- | Unfavorable | Nakano et al30 |
| High BCL2 and WT1 mRNA expression | 35/98 | 36 | Unfavorable | Unfavorable | Karakas et al31 |
| MLL partial tandem duplication | 18/221* | 8 | Unfavorable | Not significant | Döhner et al33 |
| High EVI1 mRNA expression | 32/319 | 10 | Unfavorable | Unfavorable | Van Waalwijk et al32 |
| C/EBP alpha mutation | 15/135 | 11 | Favorable | Favorable | Preudhomme et al34 |
| 12/277 | 4.3 | Favorable | Favorable | Van Waalwijk et al35 | |
| c-KIT mutation | 34/110† | 31 | Unfavorable | Not significant | Care et al36 |
| Marker . | Frequency . | (%) . | Predictive for Relapse . | Survival . | Reference . |
|---|---|---|---|---|---|
| *normal cytogenetics only. †AML with t(8;21) and inv(16) only. | |||||
| P53 mutation | 9/200 | 4.5 | -- | Unfavorable | Nakano et al30 |
| High BCL2 and WT1 mRNA expression | 35/98 | 36 | Unfavorable | Unfavorable | Karakas et al31 |
| MLL partial tandem duplication | 18/221* | 8 | Unfavorable | Not significant | Döhner et al33 |
| High EVI1 mRNA expression | 32/319 | 10 | Unfavorable | Unfavorable | Van Waalwijk et al32 |
| C/EBP alpha mutation | 15/135 | 11 | Favorable | Favorable | Preudhomme et al34 |
| 12/277 | 4.3 | Favorable | Favorable | Van Waalwijk et al35 | |
| c-KIT mutation | 34/110† | 31 | Unfavorable | Not significant | Care et al36 |